Acuitas Announces Key Partnership with Science World
Vancouver, B.C. – Acuitas Therapeutics has entered into a new, long-term partnership with
Science World, President & CEO Dr. Thomas Madden has announced. The integrated
engagement between the two organizations concentrates on human health and enrichment
education and is founded on a mutual alignment in areas such as delivering life sciences content
and promoting sciences, technology, engineering, the arts and math (STEAM) education. It will
focus on creating interest in STEAM-based careers, including participation by the Acuitas team in
Girls in STEAM and other events, with the goal of inspiring the next generation of innovators.
“Everyone on the Acuitas team is committed to promoting and supporting interest in STEAMbased careers,” said Dr. Madden. He added: “We believe that our partnership with Science World
– which is such a well-respected and well-known organization – is an exceptional opportunity for
us to proactively contribute in this area. We are delighted to be partnering with Science World and
look forward to working with them to showcase how challenging and rewarding a STEAM career
can be.”
“The team at Acuitas is passionate about building a pipeline of talent in STEAM fields and through
the work they do and have been able to positively impact millions of people all over the world,”
said Tracy Redies, Science World President and CEO. “Seeing a BC-based company achieve
what they have is truly inspiring. With their vision and goals so closely aligned with Science
World’s, we’re very excited about the long-term relationship we are building with them and we
look forward to working with their entire team.”
About Science World
Science World is a BC-based charitable organization that engages the people of British Columbia
in STEAM literacy. Their mission is to ignite wonder and empower dreams through science and
nature. Their vision is that within a generation, Canada will be a country of thriving, sustainable
communities rooted in science, innovation and a deep connection to nature.
About Acuitas Therapeutics
Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a
private biotechnology company that specializes in the development of delivery systems for nucleic
acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and
biotechnology companies and academic institutes to advance nucleic acid therapeutics into
clinical trials and to the marketplace. The team works with partners to develop new therapies to
address unmet clinical needs based on its internationally recognized capabilities in delivery
technology. Acuitas Therapeutics has agreements in place with several partners to use its
proprietary lipid nanotechnology in the development of COVID-19 vaccines. These include
Pfizer/BioNTech for COMIRNATY®, which has received full approval in the U.S. and Canada and
is authorized for Emergency Use in Europe, the UK and many other countries.
Original source here.